



AMENDMENTS TO THE CLAIMS

1. (currently amended) A PEG conjugate having the structure of the formula




wherein

n is an integer between 1 and 10;

m is an integer between 1 and 10;

R is human growth hormone or methionyl human growth hormone.

2. (currently amended) The PEG conjugate of claim 1 having the structure



wherein R is human growth hormone or methionyl human growth hormone.

3. (original) The conjugate of claim 2 wherein said human growth hormone comprises an amino acid sequence of SEQ ID NO:1.

4. (original) The conjugate of claim 2 wherein said human growth hormone consists of an amino acid sequence of SEQ ID NO:1.

5. (original) The human growth hormone-PEG conjugate of claim 3 or 4 wherein greater than 90% of said polyethylene glycol is conjugated to an amino-terminal phenylalanine of the amino acid sequence of SEQ ID NO:1.

6. (original) The human growth hormone-PEG conjugate of claim 3 or 4 wherein greater than 95% of said polyethylene glycol is conjugated to an amino-terminal phenylalanine of the amino acid sequence of SEQ ID NO:1.

7. (original) The human growth hormone-PEG conjugate of claim 5 wherein each mPEG has a molecular weight of about 20 kDa.

8. (original) The human growth hormone-PEG conjugate of claim 6 wherein each mPEG has a molecular weight of about 20 kDa.

9. (original) A composition comprising the human growth hormone-PEG conjugate of claim 7 and at least one pharmaceutically acceptable carrier.

10. (original) A method of treating a patient having a growth or development disorder comprising administering to said patient a therapeutically effective amount of the human growth hormone-PEG conjugate of claim 7.

11. (original) The method of claim 10 wherein said growth or development disorder is Growth Hormone Deficiency (GHD).

12. (original) The method of claim 10 wherein said growth or development disorder is Turner's syndrome.

13. (original) The method of claim 10 wherein said growth or development disorder is Chronic Renal Insufficiency.

14. (original) The method of claim 10 wherein said growth or development disorder is small for gestational age (SGA).

15. (original) A composition comprising the human growth hormone-PEG conjugate of claim 8 and at least one pharmaceutically acceptable carrier.

16. (original) A method of treating a patient having a growth or development disorder comprising administering to said patient a therapeutically effective amount of the human growth hormone-PEG conjugate of claim 8.

17. (original) The method of claim 16 wherein said growth or development disorder is Growth Hormone Deficiency (GHD).

18. (original) The method of claim 16 wherein said growth or development disorder is Turner's syndrome.

19. (original) The method of claim 16 wherein said growth or development disorder is Chronic Renal Insufficiency.

20. (original) The method of claim 16 wherein said growth or development disorder is small for gestational age (SGA).